Relypsa (RLYP) & Kite Pharma (KITE) Financial Analysis

Kite Pharma (NASDAQ: KITE) and Relypsa (NASDAQ:RLYP) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares Kite Pharma and Relypsa’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kite Pharma N/A N/A N/A ($6.90) -26.06
Relypsa N/A N/A N/A ($5.76) N/A

Kite Pharma is trading at a lower price-to-earnings ratio than Relypsa, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Kite Pharma and Relypsa, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kite Pharma 0 7 6 0 2.46
Relypsa 0 0 0 0 N/A

Kite Pharma currently has a consensus price target of $94.25, indicating a potential downside of 47.58%.

Insider and Institutional Ownership

87.7% of Kite Pharma shares are owned by institutional investors. 14.0% of Kite Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Kite Pharma and Relypsa’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kite Pharma -1,092.54% -59.15% -48.12%
Relypsa -1,601.53% -227.26% -115.06%

Summary

Kite Pharma beats Relypsa on 6 of the 8 factors compared between the two stocks.

Kite Pharma Company Profile

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Relypsa Company Profile

Relypsa, Inc. is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company’s technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address. Its polymers are non-absorbed, meaning they act within the gastrointestinal tract and do not get absorbed into the bloodstream or other parts of the body. Its polymer technology may be able to address many health conditions in need of viable treatment options. Its VELTASSA (patiromer) for oral suspension is a commercialized medicine resulting from its polymer technology platform. VELTASSA is a potassium binder approved for the treatment of hyperkalemia. Available in powder form, VELTASSA is mixed with water and taken daily. VELTASSA’s spherical beads bind to potassium in exchange for calcium, primarily in the colon.

Receive News & Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Churchill Downs  Upgraded by ValuEngine to Buy
Churchill Downs Upgraded by ValuEngine to Buy
ValuEngine Downgrades Hooker Furniture  to Sell
ValuEngine Downgrades Hooker Furniture to Sell
ValuEngine Upgrades PCM  to “Hold”
ValuEngine Upgrades PCM to “Hold”
Ameris Bancorp  Stock Rating Upgraded by BidaskClub
Ameris Bancorp Stock Rating Upgraded by BidaskClub
Baozun  Lowered to “Buy” at BidaskClub
Baozun Lowered to “Buy” at BidaskClub
Energen  Forecasted to Earn Q1 2018 Earnings of $0.76 Per Share
Energen Forecasted to Earn Q1 2018 Earnings of $0.76 Per Share


© 2006-2018 Ticker Report. Google+.